Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.74 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.74 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.74 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909921 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL10225106 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL4171571 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL2900521 | 0.99 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL2906042 | 0.96 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL10225102 | 0.96 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL14089212 | 0.95 | MTOR (0.90) | MTOR | |
| SCHEMBL2906090 | 0.95 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL10225112 | 0.95 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL10225127 | 0.94 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101602-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | Kudos Pharmaceuticals, Ltd. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-8101602-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | Kudos Pharmaceuticals, Ltd. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885FECH 921/4885PIK3R1 135/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | MTOR 24/4885FECH 4101/4885PIK3R1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.